Related Experiment Video

Updated: Apr 12, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

20.4K

Current concepts in minimal hepatic encephalopathy

M A Badea, Cristina Cijevschi Prelipcean, Catalina Mihai

    Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
    |May 15, 2015
    PubMed

    Insights

    Minimal hepatic encephalopathy (MHE) involves cognitive issues in liver disease patients, often missed in exams. While ammonia is key, other factors contribute, and a definitive diagnostic test is still needed.

    Area of Science:

    • Neurology
    • Hepatology
    • Gastroenterology

    Background:

    • Minimal hepatic encephalopathy (MHE) presents as neurocognitive impairments in patients with cirrhosis or portal-systemic shunting.
    • Clinical examination often shows normal neurologic and psychiatric status in MHE patients.
    • Ammonia plays a central role in MHE pathogenesis, but infection, oxidative stress, manganese, and bacterial overgrowth also contribute.

    Purpose of the Study:

    • To review the current understanding of Minimal Hepatic Encephalopathy (MHE).
    • To discuss the diagnostic challenges and contributing factors in MHE.
    • To evaluate the current recommendations for MHE treatment.

    Main Methods:

    • Literature review of studies on MHE.
    • Analysis of factors contributing to MHE pathogenesis.
    • Evaluation of diagnostic methods and treatment guidelines for MHE.

    Main Results:

    • No single gold-standard diagnostic test for MHE currently exists due to drawbacks like cost and accessibility.
    • Multiple factors beyond ammonia contribute to MHE's neurocognitive deficits.
    • MHE treatment is not routinely recommended but should be considered for specific patient groups.

    Conclusions:

    • MHE is a significant condition characterized by cognitive impairment in liver disease patients.
    • Accurate diagnosis of MHE remains challenging, necessitating further research for a gold-standard test.
    • Treatment decisions for MHE should be individualized, focusing on patients at risk for accidents or experiencing cognitive decline.

    More Related Videos

    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury07:27

    The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

    Published on: October 21, 2017

    12.5K
    Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats08:47

    Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

    Published on: November 8, 2018

    12.2K

    Related Concept Videos

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

    Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

    In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
    263
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    353
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    352
    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

    Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

    In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
    324
    Esophageal Varices-II: Clinical Features and Management01:28

    Esophageal Varices-II: Clinical Features and Management

    Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
    In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
    811
    Hepatic Drug Excretion: Influencing Factors01:16

    Hepatic Drug Excretion: Influencing Factors

    The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
    765